Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 227

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 10
Chunk 227
---
 agreement and for 24 months after cessation of employment, carry on business in competition with the Company.

Grants of Plan-Based Awards

Except as stated above, no plan-based awards were granted to any of our named executive officers during the interim fiscal year ended December 31, 2024.

Outstanding Equity Awards at Interim Fiscal Year End

The equity awards reflected in the Summary Compensation Table above represents all restricted stock awards issued to our executive officers as of December 31, 2024. No other stock or stock option awards were granted to any other officer of the Company as of December 31, 2024.

Option Exercises and Stock Vested

No option to purchase our capital stock was exercised by any of our named executive officers, nor was any restricted stock held by such executive officers vested during the interim fiscal period ended December 31, 2024.

 54Table of Contents

Pension Benefits

No named Executive Officers received or held pension benefits during the interim fiscal period ended December 31, 2024.

Item 12. Security Ownership of Certain Beneficial Owners and Management

The following table sets forth certain information, as of the date hereof, with respect to the beneficial ownership of the outstanding common stock by (i) any holder of more than five percent (5%); (ii) each of our executive officers and directors; and (iii) our directors and executive officers as a group. Except as otherwise indicated, each of the stockholders listed below has sole voting and investment power over the shares beneficially owned. The information is based on 17,967,663 shares of common stock issued and outstanding as of this filing.

Name and address of beneficial owners Amount andnature ofbeneficialownership ofCommon Stock  Approximatepercentage ofoutstandingCommon Stock (1)        Resigned Directors and Named Executive Officers:      Koon Wai Wong (2)  100   0.00%Wei Foong Lim (3)  362,936   2.02%All directors and executive officers as a group (2 persons)                 New Directors and Named Executive Officers:        Jook Yuen Low (4)  12,616   0.00%         Directors and Named Executive Officers:        Su-Leng Tan Lee (5)  -   - Muhammad Azrul bin Abdul Hamid (6)  -   - Chee Keong Yap (7)